Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2016

View Archived Issues

Phase I/II results for novel maternal trivalent GBS vaccine

Boehringer Ingelheim enrolls first patient in LUME-Meso study of nintedanib

Abide Therapeutics begins enrollment and dosing in ABX-1431 study

Novel pGX2303 vaccine provides full protection against RSV in animal model

ONO-954 compared to latanoprost in glaucoma/ocular hypertension trial

Shionogi updates progress of fourth quarter of fiscal 2015

EvOx Therapeutics raises seed funding for the development of novel exosome therapy technology

Takeda reports highlights of fourth quarter of fiscal 2015

Johns Hopkins University discloses PSMA imaging agents

Merck & Co. announces JAK inhibitors

Incyte patents FGFR-4 inhibitors

Bristol-Myers Squibb introduces PI3Kdelta inhibitors

Takeda Pharmaceutical present RBP4-lowering agents

Ono Pharmaceutical introduces voltage-gated channel activators

European Commission approves CSL Behring's Idelvion

FDA awards orphan drug designation for selumetinib as adjuvant treatment of DTC

Phase I/II results show activity of IMMU-130 in pretreated metastatic colorectal cancer

Biomarker discoveries from the Annual Meeting of the American Academy of Neurology

CIADM begins advanced development of anthrax vaccine

Boehringer Ingelheim, LDC and Max Planck sign agreement to develop schizophrenia treatment

Jazz Pharmaceuticals completes Alize Pharma II acquisition

European Commission approves BMS and AbbVie's elotuzumab

Santen to withdraw DE-109 MAA with plans to resubmit

Stellar Biotechnologies and Neovacs join to create Neostell

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...